Natera Inc (NTRA)
37.19
-0.32 (-0.85%)
USD |
NASDAQ |
Nov 29, 16:00
37.19
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.055B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -59.22% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.601 |
| Price to Book Value | 11.21 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.9167 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 77.74% |
News
Headline
Wire
Time (ET)
PR Newswire
11/23 08:33
Yahoo
11/21 08:33
Globe Newswire
11/19 20:07
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/24/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/24/2023* | -- | Results | Q4 2022 | -- | -1.48 | -- | |
| 11/08/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | -1.25 | -1.44 | 13.19% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -1.50 | -1.50 | -0.10% | |
| 05/05/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | -1.45 | -1.52 | 4.40% |
*Estimated Date/Time
Earnings
Profile
Edit
| Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. |
| URL | https://www.natera.com |
| Investor Relations URL | https://investor.natera.com |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of November 29, 2022.
Fundamentals
| Revenue (TTM) | 776.00M |
| Total Expenses (TTM) | 1.315B |
| Net Income (TTM) | -545.79M |
| Total Assets (Quarterly) | 1.009B |
| Total Liabilities (Quarterly) | 647.49M |
| Shareholders Equity (Quarterly) | 361.62M |
| Cash from Operations (TTM) | -449.11M |
| Cash from Investing (TTM) | 387.92M |
| Cash from Financing (TTM) | 22.98M |
Ratings
Profile
Edit
| Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result. |
| URL | https://www.natera.com |
| Investor Relations URL | https://investor.natera.com |
| HQ State/Province | Texas |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Feb. 24, 2023 (est.) |
| Last Earnings Release | Nov. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| AOFCX | 121.99M USD | 3.86% |
| FRTY | 1.193M USD | 3.74% |
| GNOM | 6.506M USD | 3.26% |
| ASPYX | 99.16M USD | 2.50% |
| ATFV | 205463.0 USD | 2.07% |
| CCRIX | 24.73M USD | 1.71% |
| LIACX | 41.30M USD | 1.63% |
| HAPY | 83797.00 USD | 1.23% |
| ACIZX | 28.84M USD | 1.18% |
| GTSDX | 24.50M USD | 1.08% |
| BTEC | 537631.0 USD | 0.99% |
| BBH | 3.703M USD | 0.73% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NTRA Tweets |